These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 21293802)

  • 1. Development of a fluorescent method for detecting the onset of coagulation in human plasma on microstructured lateral flow platforms.
    Dudek MM; Kent NJ; Gu P; Fan ZH; Killard AJ
    Analyst; 2011 May; 136(9):1816-25. PubMed ID: 21293802
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fluorescence-based blood coagulation assay device for measuring activated partial thromboplastin time.
    Dudek MM; Kent N; Gustafsson KM; Lindahl TL; Killard AJ
    Anal Chem; 2011 Jan; 83(1):319-28. PubMed ID: 21121686
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of a point of care lateral flow device for measuring human plasma fibrinogen.
    Dudek MM; Lindahl TL; Killard AJ
    Anal Chem; 2010 Mar; 82(5):2029-35. PubMed ID: 20131873
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of the sensitivity of an in vitro high frequency ultrasound device to monitor the coagulation process: study of the effects of heparin treatment in a murine model.
    Callé R; Rochefort GY; Desbuards N; Plag C; Antier D; Ossant F
    Ultrasound Med Biol; 2010 Feb; 36(2):295-305. PubMed ID: 20045589
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical evaluation of new global clotting assay for monitoring of LMWH treatment: pilot study.
    Makris PE; Pithara E
    Int Angiol; 1998 Jun; 17(2):69-79. PubMed ID: 9754892
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Magnetoelastic transducers for monitoring coagulation, clot inhibition, and fibrinolysis.
    Puckett LG; Lewis JK; Urbas A; Cui X; Gao D; Bachas LG
    Biosens Bioelectron; 2005 Mar; 20(9):1737-43. PubMed ID: 15681188
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Surface-adsorbed fibrinogen and fibrin may activate the contact activation system.
    Sanchez J; Elgue G; Larsson R; Nilsson B; Olsson P
    Thromb Res; 2008; 122(2):257-63. PubMed ID: 18177925
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of fibrinogen concentration in severely ill patients on mechanical properties of whole blood clots.
    Dempfle CE; Kälsch T; Elmas E; Suvajac N; Lücke T; Münch E; Borggrefe M
    Blood Coagul Fibrinolysis; 2008 Dec; 19(8):765-70. PubMed ID: 19002042
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A new global assay of coagulation and fibrinolysis.
    Goldenberg NA; Hathaway WE; Jacobson L; Manco-Johnson MJ
    Thromb Res; 2005; 116(4):345-56. PubMed ID: 16038720
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of the automated coagulation analyzer Sysmex CA-7000.
    Fischer F; Appert-Flory A; Jambou D; Toulon P
    Thromb Res; 2006; 117(6):721-9. PubMed ID: 16098565
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Heparin dosing and monitoring for cardiopulmonary bypass. A comparison of techniques with measurement of subclinical plasma coagulation.
    Gravlee GP; Haddon WS; Rothberger HK; Mills SA; Rogers AT; Bean VE; Buss DH; Prough DS; Cordell AR
    J Thorac Cardiovasc Surg; 1990 Mar; 99(3):518-27. PubMed ID: 2308370
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Investigation of prothrombin time in human whole-blood samples with a quartz crystal biosensor.
    Müller L; Sinn S; Drechsel H; Ziegler C; Wendel HP; Northoff H; Gehring FK
    Anal Chem; 2010 Jan; 82(2):658-63. PubMed ID: 20000697
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The fibrinogen functional turbidimetric assay.
    Stief TW
    Clin Appl Thromb Hemost; 2008 Jan; 14(1):84-96. PubMed ID: 18160594
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Simultaneous determination of coagulation and fibrinolysis parameters for diagnostics of disseminated intravascular blood coagulation (DIC).
    Lezhen T; Kramarev S; Kolesnik L; Kudinov S
    Mater Med Pol; 1992; 24(2):79-81. PubMed ID: 1307773
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anticoagulation monitoring.
    Ng VL
    Clin Lab Med; 2009 Jun; 29(2):283-304. PubMed ID: 19665679
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Monitoring of heparins in haemodialysis using an anti-factor-Xa-specific whole-blood clotting assay.
    Harenberg J; Haaf B; Dempfle CE; Stehle G; Heene DL
    Nephrol Dial Transplant; 1995; 10(2):217-22. PubMed ID: 7753456
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Detection of an abnormal plasma clot structure by a simple rigidity assay.
    Carr ME; Blatt PM; Roberts HR; Brooker JZ; Hermans J
    Thromb Haemost; 1979 Oct; 42(3):965-71. PubMed ID: 505410
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessment by transient elastography of the viscoelastic properties of blood during clotting.
    Gennisson JL; Lerouge S; Cloutier G
    Ultrasound Med Biol; 2006 Oct; 32(10):1529-37. PubMed ID: 17045874
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The significance of TFPI in clotting assays--comparison and combination with other anticoagulants.
    Nordfang O; Kristensen HI; Valentin S; Ostergaard P; Wadt J
    Thromb Haemost; 1993 Sep; 70(3):448-53. PubMed ID: 8259547
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Monitoring high-dose heparinization during cardiopulmonary by-pass--a comparison between prothrombinase-induced clotting time (PiCT) and two chromogenic anti-factor Xa activity assays.
    Raivio P; Kuitunen A; Petäjä J; Ilveskero S; Lassila R
    Thromb Haemost; 2008 Feb; 99(2):427-34. PubMed ID: 18278195
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.